Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Non Operating Income: 2019-2024

Historic Non Operating Income for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $27.0 million.

  • 4D Molecular Therapeutics' Non Operating Income fell 40.88% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year decrease of 14.84%. This contributed to the annual value of $27.0 million for FY2024, which is 124.21% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Non Operating Income stood at $27.0 million, which was up 124.21% from $12.0 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Non Operating Income registered a high of $27.0 million during FY2024, and its lowest value of -$181,000 during FY2020.
  • Over the past 3 years, 4D Molecular Therapeutics' median Non Operating Income value was $12.0 million (recorded in 2023), while the average stood at $13.8 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 112.41% in 2020, then surged by 2,197.52% in 2022.
  • Over the past 5 years, 4D Molecular Therapeutics' Non Operating Income (Yearly) stood at -$181,000 in 2020, then soared by 33.15% to -$121,000 in 2021, then soared by 2,197.52% to $2.5 million in 2022, then spiked by 374.00% to $12.0 million in 2023, then spiked by 124.21% to $27.0 million in 2024.